Eyepoint's Duravyu Fails Phase 3 Goal, Stock Plunges — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eyepoint said Monday that patients given its experimental treatment Duravyu failed to maintain vision with less frequent injections compared to a standard treatment in a Phase 3 trial
- The study fell short of its primary goal, imperiling Eyepoint's plans to seek regulatory approval for Duravyu, though the company still sees promise
- Eyepoint's stock price plummeted in reaction to the Phase 3 readout
- Shares of Ocular Therapeutix, maker of a competing eye treatment expected to be submitted to the FDA later this year, rose on the news
- Both companies are developing drugs for wet age-related macular degeneration that require fewer eye injections than currently approved treatments
Why it matters: The Phase 3 failure puts Eyepoint's regulatory path for Duravyu in doubt and triggered an opposite-direction move in two rival stocks — Eyepoint plunging while Ocular Therapeutix rose — clearing competitive ground for Ocular's wet AMD drug heading to the FDA later this year.
Ask SkimNews
